Acknowledgements
We thank all participants for taking part in this study. We thank Jennifer Dobson for proofreading this manuscript.
Author contributions
MB - Conception, Organization, Execution, Writing of the first draft, Manuscript review and critique, AC - Conception, Organization, Execution, Writing of the first draft, Manuscript review and critique, MS - Conception, Organization, Execution, Writing of the first draft, Manuscript review and critique, EL - Conception, Organization, Execution, Writing of the first draft, Manuscript review and critique, AG - Conception, Organization, Execution, Writing of the first draft, Manuscript review and critique, AB - Execution, Manuscript review and critique, PP - Execution, Manuscript review and critique, ES - Execution, Manuscript review and critique, HK - Execution, Manuscript review and critique, NL - Execution, Manuscript review and critique, TW - Execution, Manuscript review and critique, VF - Execution, Manuscript review and critique, IB - Execution, Manuscript review and critique, FD - Execution, Manuscript review and critique, JPA - Execution, Manuscript review and critique, EM - Execution, Manuscript review and critique, EB - Execution, Manuscript review and critique, ST - Execution, Manuscript review and critique, CT - Execution, Manuscript review and critique, PK - Conception, Organization, Execution, Writing of the first draft, Manuscript review and critique, MA - Conception, Organization, Execution, Writing of the first draft, Manuscript review and critique.
Data availability
Anonymized data of this study will be available from the corresponding author on reasonable request from any qualified researcher, following the EU General Data Protection Regulation. The study protocol and statistical analysis plan will be shared upon request.
Funding
This study was ancillary to the “Honeymoon” study, for which UCB provided financial support. The sponsor had no role in the study design, data analysis and interpretation, or in writing the manuscript.
Competing interests
Dr Béreau reports reimbursement of travel expenses to scientific meetings from ELIVIE, Medtronic and Boston Scientific, honoraria from Merz Pharma and Allergan for lecturing outside the submitted work.
Dr Castrioto reports research grants from France Parkinson Foundation and Medtronic, honoraria from ELIVIE for lecturing outside the submitted work.
Dr. Wirth reports research grant from the French Society of Neurology, the APTES and the Fondation Planiol organizations and travels reimbursement from LVL medical outside the submitted work.
Dr. Fraix reports reimbursement of travel expenses from Merz, AbbVie, honoraria for scientific counselling from AbbVie outside the submitted work.
Dr. Azulay reports honoraria for consultancies and advisory boards from Abbvie, Merz, Allergan, Medtronic, Ever Pharma outside the submitted work.
Dr. Moro reports honorarium from Medtronic and Newronica for lecturing, and an educational grant from Boston outside the submitted work.
Dr Thobois reports grants from France Parkinson, FRM, ANR, PHRC, UCB, Neurodis, personal fees from Aguettant, Boston Scientific, Novartis, non-financial support from Zambon, Abbvie, Elivie outside the submitted work.
Dr. Tranchant reports reimbursement of travel expenses from Merz, and honoraria from Allergan for lecturing outside the submitted work.
Dr. Krack reports a research grant from UCB for the present study, research grants from Swiss National Science Foundation, ROGER DE SPOELBERCH Foundation, Bertarelli Foundation, Annemarie Opprecht Foundation, Parkinson Schweiz, Boston Scientific, and Aleva, lecturing fees paid to employing institution (Inselspital) from Boston Scientific, as well as reimbursement of travelling expenses to scientific meeting by Zambon outside the submitted work.
Dr Anheim reports travel grants and/or honoraria from Actelion Pharmaceuticals, Johnson and Johnson, Teva, LVL, Aguettant, Orkyn, AbbVie and Merz outside the submitted work
Ethical approval This cross-sectional study was ancillary to the “Honeymoon” study, a French prospective multicenter trial. The “Honeymoon” study was approved by the Ethics Committee of Grenoble, authorized by the National Agency for the Safety of Medicines and Health Products (AFSSAPS), and registered as NCT02786667. All patients included in the study gave written informed consent in accordance with local legislation.